FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073529062> ?p ?o ?g. }

• W2073529062 endingPage "440" @default.
• W2073529062 startingPage "434" @default.
• W2073529062 abstract "Purpose: To evaluate the therapeutic results obtained with 192Ir low-dose-rate interstitial brachytherapy in T2N0 mobile tongue carcinoma. Patients and Methods: Between December 1979 and January 1998, 279 patients with T2N0 mobile tongue carcinoma were treated by exclusive low-dose-rate brachytherapy, with or without neck dissection. 192Ir brachytherapy was performed according to the “Paris system” with a median total dose of 60 Gy (median dose rate, 0.5 Gy/h). Results: Overall survival was 74.3% and 46.6% at 2 and 5 years. Local control was 79.1% at 2 years and regional control, respectively, 75.9% and 69.5% at 2 and 5 years (Kaplan–Meier method). Systematic dissection revealed 44.6% occult node metastases, and histologic lymph node involvement was identified as the main significant factor for survival. Complication rate was 16.5% (Grade 3, 2.9%). Half of the patients presented previous and/or successive malignant tumor (ear-nose-throat, esophagus, or bronchus). Conclusion: Exclusive low-dose-rate brachytherapy is an effective treatment for T2 tongue carcinoma. Regional control and survival are excellent in patients undergoing systematic neck dissection, which is mandatory in our experience because of a high rate of occult lymph node metastases. Purpose: To evaluate the therapeutic results obtained with 192Ir low-dose-rate interstitial brachytherapy in T2N0 mobile tongue carcinoma. Patients and Methods: Between December 1979 and January 1998, 279 patients with T2N0 mobile tongue carcinoma were treated by exclusive low-dose-rate brachytherapy, with or without neck dissection. 192Ir brachytherapy was performed according to the “Paris system” with a median total dose of 60 Gy (median dose rate, 0.5 Gy/h). Results: Overall survival was 74.3% and 46.6% at 2 and 5 years. Local control was 79.1% at 2 years and regional control, respectively, 75.9% and 69.5% at 2 and 5 years (Kaplan–Meier method). Systematic dissection revealed 44.6% occult node metastases, and histologic lymph node involvement was identified as the main significant factor for survival. Complication rate was 16.5% (Grade 3, 2.9%). Half of the patients presented previous and/or successive malignant tumor (ear-nose-throat, esophagus, or bronchus). Conclusion: Exclusive low-dose-rate brachytherapy is an effective treatment for T2 tongue carcinoma. Regional control and survival are excellent in patients undergoing systematic neck dissection, which is mandatory in our experience because of a high rate of occult lymph node metastases." @default.
• W2073529062 created "2016-06-24" @default.
• W2073529062 creator A5023419803 @default.
• W2073529062 creator A5058092517 @default.
• W2073529062 creator A5076536874 @default.
• W2073529062 creator A5079019482 @default.
• W2073529062 creator A5085981285 @default.
• W2073529062 creator A5088786256 @default.
• W2073529062 creator A5089432161 @default.
• W2073529062 date "2005-10-01" @default.
• W2073529062 modified "2023-10-17" @default.
• W2073529062 title "Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma" @default.
• W2073529062 cites W134239710 @default.
• W2073529062 cites W1970506770 @default.
• W2073529062 cites W1974080135 @default.
• W2073529062 cites W1975165637 @default.
• W2073529062 cites W1975419271 @default.
• W2073529062 cites W1978069724 @default.
• W2073529062 cites W1978730416 @default.
• W2073529062 cites W1987252838 @default.
• W2073529062 cites W1988213517 @default.
• W2073529062 cites W2005083978 @default.
• W2073529062 cites W2005627485 @default.
• W2073529062 cites W2006022271 @default.
• W2073529062 cites W2011877575 @default.
• W2073529062 cites W2014343199 @default.
• W2073529062 cites W2016894334 @default.
• W2073529062 cites W2023405221 @default.
• W2073529062 cites W2023749553 @default.
• W2073529062 cites W2023793092 @default.
• W2073529062 cites W2024977321 @default.
• W2073529062 cites W2031757466 @default.
• W2073529062 cites W2035463734 @default.
• W2073529062 cites W2036443073 @default.
• W2073529062 cites W2037371434 @default.
• W2073529062 cites W2040580718 @default.
• W2073529062 cites W2042606708 @default.
• W2073529062 cites W2048195344 @default.
• W2073529062 cites W2049469742 @default.
• W2073529062 cites W2064786905 @default.
• W2073529062 cites W2067979431 @default.
• W2073529062 cites W2069200743 @default.
• W2073529062 cites W2076139318 @default.
• W2073529062 cites W2078098100 @default.
• W2073529062 cites W2078188421 @default.
• W2073529062 cites W2084515494 @default.
• W2073529062 cites W2085237860 @default.
• W2073529062 cites W2088801273 @default.
• W2073529062 cites W2115424417 @default.
• W2073529062 cites W2123073869 @default.
• W2073529062 cites W2146585776 @default.
• W2073529062 cites W2164019656 @default.
• W2073529062 cites W2415685275 @default.
• W2073529062 doi "https://doi.org/10.1016/j.ijrobp.2005.02.014" @default.
• W2073529062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16168836" @default.
• W2073529062 hasPublicationYear "2005" @default.
• W2073529062 type Work @default.
• W2073529062 sameAs 2073529062 @default.
• W2073529062 citedByCount "37" @default.
• W2073529062 countsByYear W20735290622012 @default.
• W2073529062 countsByYear W20735290622013 @default.
• W2073529062 countsByYear W20735290622014 @default.
• W2073529062 countsByYear W20735290622015 @default.
• W2073529062 countsByYear W20735290622016 @default.
• W2073529062 countsByYear W20735290622017 @default.
• W2073529062 countsByYear W20735290622018 @default.
• W2073529062 countsByYear W20735290622020 @default.
• W2073529062 countsByYear W20735290622021 @default.
• W2073529062 countsByYear W20735290622022 @default.
• W2073529062 countsByYear W20735290622023 @default.
• W2073529062 crossrefType "journal-article" @default.
• W2073529062 hasAuthorship W2073529062A5023419803 @default.
• W2073529062 hasAuthorship W2073529062A5058092517 @default.
• W2073529062 hasAuthorship W2073529062A5076536874 @default.
• W2073529062 hasAuthorship W2073529062A5079019482 @default.
• W2073529062 hasAuthorship W2073529062A5085981285 @default.
• W2073529062 hasAuthorship W2073529062A5088786256 @default.
• W2073529062 hasAuthorship W2073529062A5089432161 @default.
• W2073529062 hasBestOaLocation W20735290621 @default.
• W2073529062 hasConcept C126322002 @default.
• W2073529062 hasConcept C126838900 @default.
• W2073529062 hasConcept C141071460 @default.
• W2073529062 hasConcept C142724271 @default.
• W2073529062 hasConcept C2775862295 @default.
• W2073529062 hasConcept C2776283816 @default.
• W2073529062 hasConcept C2777416452 @default.
• W2073529062 hasConcept C2777546739 @default.
• W2073529062 hasConcept C2778474501 @default.
• W2073529062 hasConcept C2779744641 @default.
• W2073529062 hasConcept C2780849966 @default.
• W2073529062 hasConcept C509974204 @default.
• W2073529062 hasConcept C71924100 @default.
• W2073529062 hasConceptScore W2073529062C126322002 @default.
• W2073529062 hasConceptScore W2073529062C126838900 @default.
• W2073529062 hasConceptScore W2073529062C141071460 @default.
• W2073529062 hasConceptScore W2073529062C142724271 @default.
• W2073529062 hasConceptScore W2073529062C2775862295 @default.
• W2073529062 hasConceptScore W2073529062C2776283816 @default.

• next